Thank you CBC for covering our latest study using
#proteomics and rapid patient derived models to inform patient care - out in EMBO Molecular Medicine.

A first in Canada step towards improved personalized #PrecisionMedicine

CBC: www.cbc.ca/player/play/...
Article: www.embopress.org/doi/full/10....

Next up: Dr Michael Lassman from Merck giving the 2nd Keynote at #CNPN2024.

@lkpino.bsky.social @talusbio.bsky.social kicking off the BC Proteomics & Metabolomics Network Symposium with a phenomenal keynote. Transcription factors, mass spec in drug development, startups, off target effects, … beautiful tour de force. #proteomics.sky

First timsTOF Ultra in Canada🇨🇦 installed (Dec 2023) @BC Children's & @ubcmedicine.bsky.social. We were busy with our first neuroblastoma cohort so forgot to share this exciting news here. Heartfelt thanks to our donors & BC Children's Hospital Foundation! #TeamMassSpec #Proteomics #Cancer

🌟 Early Holiday Cheer at @BCCHresearch 🌟

🎁Thanks to @BCCHF and all our amazing donors for the generous gift that arrived today!

This will turbocharge our research towards a future where every kid has #ACCESS to proteome guided therapy 💪⚖️.

#PrecisionMedicine #ChildhoodCancer #CanSky #OncoSky

Excited to be @SickKids in Toronto for the inaugural meeting of @CIHR_IRSC #CPCC - Canadian Pediatric Cancer Consortium, now #ACCESS - to discuss how we can Advance #ChildhoodCancer Experiences Science & Survivorship. We have big plans - stay tuned. @BCCHresearch #CanSky #OncoSky

Proteomics highlighted PARP1 as a possible treatment target and Amanda could confirm in vitro sensitivity of primary patient cells to two PARP1 inhibitors. 5/5

Proteome classification separated patients with good and poor event-free survival more clearly than clinical high/low risk classification. 4/

Mass spectrometry based proteomics analysis showed that leukemic cells from the same patient had stable proteomes across disease progression. The abundance of many key proteins was statistically equivalent. 3/

Using a pediatric focussed targeted sequencing panel identifies the same therapy options at diagnosis and relapse for >60% of patients. But as shown before the correlation between sensitivity predicted based on genetic variants and in vitro sensitivity is poor. 2/

Happy to share the phenomenal PhD work of Dr. Amanda Lorentzian now out in its peer-reviewed from in @NatureComms. Amanda shows that targetable genome variants and proteome features are mostly stable from diagnosis to relapse in pediatric leukemia. 1/ www.nature.com/articles/s41...

Join us! To accelerate our activities in the Canadian Pediatric Cancer Consortium and PROFYLE we have multiple opportunities to study sarcomas, brain tumours, infant leukemias and employ proteomics to identify treatment options-today. #oncosky #TeamMassSpec
Details langelab.med.ubc.ca/open-positions

Made my way here. Hope I can help to recreate a great SciTwitter community #hiscisky

Nice and great mode of introduction to #hiscisky.